Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

The Effect of Gender-Affirming Testosterone Therapy on Cardiovascular Health in Transmasculine Individuals

EF 2022-23

Résumé
The transgender population (gender identity differs from sex assigned at birth) is expected to reach 25 million globally and are at a greater risk for cardiovascular disease compared to their cisgender (sex assigned at birth aligns with gender identity) counterparts. There is a lack of research aimed at understanding the pathogenesis of cardiovascular events in transmasculine individuals (assigned female sex at birth who identify as men), resulting in significant clinical uncertainty. The use of gender-affirming testosterone therapy (GATT) by transmasculine individuals has increased, allowing for the acquisition of masculinizing secondary sex characteristics. Testosterone replacement therapy in cisgender men and high testosterone levels in cisgender women have been associated with adverse effects on cardiovascular health. Furthermore, the route by which testosterone is administered (e.g., oral, transdermal, injection) may also affect cardiovascular risk. However, how testosterone affects cardiovascular health in the transmasculine population is unclear, highlighting an important knowledge gap. Therefore, this research program will explore the effects of GATT in transmasculine individuals, with a specific focus on how the way these hormones are taken (by creams, gels, patches vs. injection) affect cardiovascular health. The transgender population is a growing yet medically underserved population. Despite increased cardiovascular risk, no evidence-based interventions for risk reduction specific to the transgender population exist to-date. The results of this patient-partnered work will directly inform shared decision-making by transmasculine individuals and their health care providers.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486189
Name
Pattar Badal S
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Effect of Gender-Affirming Testosterone Therapy on Cardiovascular Health in Transmasculine Individuals
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Arterial Stiffness; Cardiovascular Disease; Gender-Affirming Therapy; Injection; Renin Angiotensin Aldosterone System; Sex & Gender; Testosterone; Transdermal; Transgender Health; Transmasculine
Abstract
The transgender population (gender identity differs from sex assigned at birth) is expected to reach 25 million globally and are at a greater risk for cardiovascular disease compared to their cisgender (sex assigned at birth aligns with gender identity) counterparts. There is a lack of research aimed at understanding the pathogenesis of cardiovascular events in transmasculine individuals (assigned female sex at birth who identify as men), resulting in significant clinical uncertainty. The use of gender-affirming testosterone therapy (GATT) by transmasculine individuals has increased, allowing for the acquisition of masculinizing secondary sex characteristics. Testosterone replacement therapy in cisgender men and high testosterone levels in cisgender women have been associated with adverse effects on cardiovascular health. Furthermore, the route by which testosterone is administered (e.g., oral, transdermal, injection) may also affect cardiovascular risk. However, how testosterone affects cardiovascular health in the transmasculine population is unclear, highlighting an important knowledge gap. Therefore, this research program will explore the effects of GATT in transmasculine individuals, with a specific focus on how the way these hormones are taken (by creams, gels, patches vs. injection) affect cardiovascular health. The transgender population is a growing yet medically underserved population. Despite increased cardiovascular risk, no evidence-based interventions for risk reduction specific to the transgender population exist to-date. The results of this patient-partnered work will directly inform shared decision-making by transmasculine individuals and their health care providers.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pattar, Badal S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~